An Open-Label, Dose-Escalation Study of AZD2461
NCT01247168
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
75
Enrollment
INDUSTRY
Sponsor class
Conditions
Refractory Solid Tumors
Cancer Tumor
Interventions
DRUG:
AZD2461
Sponsor
AstraZeneca